Novo Nordisk’s Critical Crossroads: A December Reckoning

Novo Nordisk DK0062498333

The investment case for Danish pharmaceutical giant Novo Nordisk appears to be in tatters as 2025 unfolds, with its equity value having collapsed by more than half since January. Facing brutal price competition and legal setbacks, anxious shareholders are now focusing on a single date in early December. The central question is whether a potential breakthrough in Alzheimer’s research can reverse the company’s fortunes or if a complete collapse is imminent.